- No Shareholder Action Required at This Time
WASHINGTON, June 6, 2024
/PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the
"Company") (Nasdaq: VNDA) today confirmed that it has received an
unsolicited, non-binding indication of interest from Cycle Group
Holdings Ltd. ("Cycle Group") to acquire the Company for
$8.00 per share in cash.
Consistent with its fiduciary duties, and in consultation with
its independent financial and legal advisors, the Vanda Board of
Directors (the "Board") will carefully review and evaluate the
indication of interest to determine the course of action that the
Board believes is in the best interests of Vanda and its
shareholders.
Vanda does not intend to comment further on the indication of
interest before the Board has completed its review.
There is no action for shareholders to take at this time.
About Vanda Pharmaceuticals Inc.
Vanda is a
leading global biopharmaceutical company focused on the development
and commercialization of innovative therapies to address high unmet
medical needs and improve the lives of patients. For more on Vanda
Pharmaceuticals Inc., please visit www.vandapharma.com and follow
us on X @vandapharma.
Cautionary Note Regarding Forward Looking
Statements
Various statements in this press release,
including, but not limited to, statements regarding the Board's
intention to review Cycle Group's indication of interest are
"forward-looking statements" under securities laws. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Forward-looking statements
are based upon current expectations and assumptions that involve
risks, changes in circumstances and uncertainties. Therefore, no
assurance can be given that the results or developments anticipated
by Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Forward-looking statements in this press release should be
evaluated together with the various risks and uncertainties that
affect Vanda's business and market, particularly those identified
in the "Cautionary Note Regarding Forward-Looking Statements",
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of Vanda's
most recent Annual Report on Form 10-K, as updated by Vanda's
subsequent Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the U.S. Securities and Exchange
Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this press release is
provided only as of the date of this press release, and Vanda
undertakes no obligation, and specifically declines any obligation,
to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Vanda Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan
Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-confirms-receipt-of-unsolicited-non-binding-indication-of-interest-from-cycle-group-holdings-ltd-302166196.html
SOURCE Vanda Pharmaceuticals Inc.
